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Abstract
Breast cancer is a major health concern for many women, but despite the current standard
therapies, many women still die of metastatic disease. Angiogenesis has been evaluated as a
possible target for therapy and bevacizumab (Avastin®, Genentech/Roche, CA, USA), a
monoclonal antibody against VEGF-A, has been developed to target this. Current clinical trials
utilizing bevacizumab have shown an increase in progression-free survival, but this has not
translated to an increase in overall survival in breast cancer patients. In this article, we summarize
the currently published trials utilizing bevacizumab in the treatment of breast cancer and describe
various methods of measuring angiogenesis in vitro and in vivo. We also describe the related
process of lymphangiogenesis, as this may contribute to the mechanism of cancer progression and
may be a potential target for therapy in the future. Understanding these processes may help us
develop new treatments for breast cancer.
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Breast cancer is the second most common cancer occurring in women in the USA, with one
in eight diagnosed with the disease during their lifetime [1]. Every year, approximately
230,000 new cases of invasive breast cancer will be diagnosed, and approximately 40,000
women will die of this disease [1]. Therefore, the search for new therapies to combat breast
cancer is of great importance to women’s health. Therapeutic interventions target various
components that contribute to cancer progression and metastasis including angiogenesis, the
generation of new blood vessels. Here, we will review the data from recently concluded
clinical trials on angiogenesis-targeted therapy utilizing bevacizumab, a humanized
monoclonal antibody that recognizes and blocks VEGF-A.
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Role of angiogenesis in cancer progression
Judah Folkman described the concept of tumor angiogenesis as a requirement for tumor
growth in 1971 [2]. It has long been accepted that tumor growth beyond a diameter of a few
millimeters requires generation of new vessels from existing ones. Folkman observed that
this new growth of vessels in a tumor is even more vigorous than that observed in fresh
wounds or inflammatory beds. He hypothesized that there is interplay between the tumor
cells and the proliferating vascular endothelial cells, and that a solid tumor obtains its new
blood vessels from the host. Folkman showed that a tumor implant of 2–3 mm in diameter,
consisting of less than 1 million cells, induces DNA synthesis in the local, previously
quiescent endothelial cells of capillaries and venules in as little as 6 h after tumor
implantation [2]. He observed that this proliferation continued even when the tumor was
separated from the vasculature by a filter that prevented the passage of cells. This result
implied that the stimulus for this growth had to be a factor, or factors, secreted by the cells
that diffuse across a tissue bed. This mechanism is also thought to contribute to the
development of metastatic disease. Folkman demonstrated that factors released by tumors
mediate angiogenesis [3], and he isolated a factor that he termed tumor angiogenesis factor,
which caused endothelial cell proliferation and capillary formation, from various tumors [2].
He theorized that blocking the action of factors such as tumor angiogenesis factor could
arrest tumor growth, and he coined the term ‘antiangiogenesis’ to describe the prevention of
generation of new vessels in a tumor [2].
Vascular permeability factor, later termed VEGF, was first discovered in 1983 and was later
shown to be secreted by tumors and to stimulate angiogenesis in a similar way to tumor
angiogenesis factor [4]. VEGF has been identified as an ideal target for Folkman’s proposed
antiangiogenesis treatment, as this will theoretically inhibit growth of the primary tumor as
well as metastatic tumors. Weidner et al. showed that a higher density of blood vessels in a
tumor is an independent and significant prognostic indicator for overall and relapse-free
survival in patients with early-stage breast cancer [5]. Multiple proangiogenic proteins that
are produced by tumor cells have been identified, and VEGF is the major or sole
proangiogenic protein expressed by breast cancers in 60% of women at the time of first
diagnosis [6].
VEGF was later termed VEGF-A, with the discovery of multiple isoforms, and has been the
most extensively studied [7]. It was found to play a significant role in the process of
angiogenesis, and was discovered to be regulated by HIF1-α [7,8]. VEGF-A and its
isoforms, VEGF-B, VEGF-C and VEGF-D, were found to act on two tyrosine kinase
receptors, termed VEGF receptor-1 and VEGF receptor-2 [7]. The mechanisms of action of
these other isoforms have not yet been studied in great detail, but are also thought to play a
role in angiogenesis and lymphangiogenesis (Figure 1) [7,8].
It has been shown since 1991 that an anti-VEGF antibody reduces the density of the blood
vessels in a given microscopic area in a tumor, termed the microvessel density, and causes
inhibition of growth of some tumors in nude mice, which rely on VEGF as their sole
mediator of angiogenesis [9]. This observation led to the recent development of
bevacizumab, a humanized monoclonal antibody that binds VEGF-A, and thus is an indirect
inhibitor of angiogenesis.
Experimental assays to measure angiogenesis
In order to develop and evaluate the potential benefit of new antiangiogenesis treatments,
reliable methods of measuring angiogenesis both in vitro and in vivo are required. The ideal
angiogenesis assay would be robust, reproducible, rapid and, most importantly, relate
directly to results seen in the clinical setting. Most in vitro assays utilize isolated blood
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endothelial cells (BECs) and focus on their proliferation, migration and tube formation, all
of which are essential for the process of angiogenesis. The isolation procedures of BECs
from different organs have recently become increasingly sophisticated and organ-specific
endothelial cells are now available as primary cell lines from commercial sources [10].
However, these cultures should be used with caution since BECs rapidly lose their
physiological properties on repeated culturing [10].
Angiogenesis does not occur unless the BECs proliferate. A common method to measure
cell proliferation is the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or
water-soluble tetrazolium salt assay (Roche, CA, USA) [11], which measure mitochondrial
activity as a reflection of cell viability, or the [3H] thymidine incorporation assay that
directly measures DNA synthesis and, hence, proliferation [12]. Critical parameters to
consider are cell passage number and cell density. In addition to proliferation, BECs need to
migrate into the perivascular stroma for angiogenesis to occur, which is commonly
evaluated using a scratch assay or a Boyden chamber assay. The scratch assay, also known
as a wound healing assay, consists of counting cells that migrate into the empty space
produced by simple scraping of a confluent monolayer of BECs [13], thus it is considered an
assessment of random cell mobility. The Boyden chamber assay utilizes a two-chambered
apparatus separated with a filter, with cells placed on top and chemoattractants in the
bottom, known as a Boyden chamber [14]. This assay assesses direct migration, or invasion,
into filters coated with a basement membrane component such as collagen or Matrigel™
(BD Biosciences, NJ, USA) [15].
The most specific in vitro assay to measure angiogenesis is the tube formation assay, which
measures the length of the capillary-like tubular structures that BECs form after being plated
on basement membrane extracts such as Matrigel [16,17]. The key to the success of this
assay is usage of a growth factor-reduced Matrigel, which avoids basal stimulation of BECs
to form tubes [18], and ensuring BECs are in early passage (two to six passages) and
approximately 80% confluent before harvesting them for use in the assay. Numerous
reviews discuss tube formation assays in greater detail [17,19,20]. Recently, some
researchers have utilized 3D assays, which are presumed to provide a more physiological
model of the differentiation and tube formation of BECs [21,22].
Several ex vivo organ culture-based angiogenesis assays have been developed. The most
described is the rat aortic ring assay, which monitors the vessels sprouting from thin rings of
the rat aorta embedded in a collagen matrix [23]. This method can be used to monitor
lymphangiogenesis when the thoracic duct is used in place of the aorta [24]. The most
commonly used in vivo assay is the Matrigel plug assay, in which Matrigel is injected
subcutaneously into mice in its liquid form at 4°C, forming a gel at body temperature.
Incorporation of various angiogenic factors in the gel matrix leads to the recruitment of
BECs and formation of a fine tubular network, where angiogenesis can be evaluated with
histological staining or injection of high-molecular weight dextran. A disadvantage of this
technique is variability between different samples due to the inconsistencies in formation of
the Matrigel plug despite injection of equal volumes.
This problem was solved in the directed in vivo angiogenesis assay where the Matrigel is
enclosed in a silicone cylinder with one open end, termed an ‘angioreactor’ [25]. The
angioreactor is filled with Matrigel, with or without test factors, and is implanted
subcutaneously into mice. The number of BECs that migrate into it can be quantified with
fluorescein isothiocyanate–dextran [25]. The directed in vivo angiogenesis assay is
considered to be the most quantitative assay to measure angiogenesis in vivo. Other assays
utilizing the chick chorioallantoic membrane [26] and corneal micropocket assay [27]
provide an in vivo environment to test the effect on angiogenesis. These techniques are
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widely used, but they are labor intensive and the results can be inconsistent because of
artifacts.
Clinical trials with bevacizumab
To date, bevacizumab has been tested in a number of trials of patients with metastatic,
locally advanced or operable breast cancer. The published trials vary with respect to the dose
and regimen of bevacizumab that is given, the agents it is combined with and the stage of
disease being treated. In these studies, bevacizumab has been used as salvage or neoadjuvant
therapy, as well as adjuvant treatment in operative cases.
Early-phase studies
One study has tested the addition of bevacizumab to endocrine therapy, since it is
hypothesized that this may delay or prevent the development of resistance to endocrine
therapy. Traina et al. treated patients in a Phase I open-label study with locally advanced or
metastatic breast cancer treated with the aromatase inhibitor letrozole 2.5 mg daily plus
bevacizumab 15 mg/kg every 3 weeks. In all, 43 patients were treated with a median of 13
cycles. A total of 84% had at least stable disease, and four patients (9%) had partial
responses, while none had a complete response. Stable disease for longer than 24 weeks was
noted in 29 patients (67%) and the median progression-free survival (PFS) was 17.1 months.
The overall clinical benefit rate was 77% [28]. Ramaswamy et al. utilized bevacizumab with
docetaxel as first- or second-line therapy for patients with metastatic breast cancer. A total
of 27 patients received bevacizumab 10 mg/kg on days 1 and 15 with docetaxel 35 mg/m2
on days 1, 8 and 15 of a 28-day cycle. A median of six cycles were given per patient. Of
these, 22% of the patients had failed prior chemotherapy. The overall response rate was
52%, with median response duration of 6.0 months and median PFS of 7.5 months [29].
Multiple other studies have evaluated the addition of bevacizumab as salvage therapy in
Phase II studies for patients who have failed prior chemotherapy. Dickler et al. treated 38
patients with metastatic breast cancer with erlotinib 150 mg daily, and bevacizumab 15 mg/
kg every 3 weeks. The patients had received one or two prior chemotherapy regimens. One
patient had a partial response for more than 52 months. A total of 15 patients had stable
disease at first evaluation at 9 weeks and four of these patients sustained the response for
more than 26 weeks. The median time to progression was 11 weeks. Overall, activity was
limited [30]. Burstein et al. treated patients who had received one or two prior chemotherapy
regimens for metastatic breast cancer or whose cancer had recurred within 12 months of
adjuvant therapy and had measurable disease, with bevacizumab 10 mg/kg every 2 weeks
and vinorelbine 25 mg/m2 every week. A total of 56 women were treated, with a 34%
response rate and median time to progression of 5.5 months. Extent of prior chemotherapy
did not appear to relate to outcomes [31].
Some Phase II studies have combined bevacizumab with metronomic chemotherapy
regimens. In one study by Dellapasqua et al., patients with advanced breast cancer received
capecitabine 500 mg three-times per day and cyclophosphamide 50 mg daily with
bevacizumab 10 mg/kg every 2 weeks. A total of 46 patients were assessed, yielding one
complete response (2%), 21 partial responses (46%), 19 patients with stable disease (41%)
and five with progressive disease (11%). Eight patients had long-term stabilization, defined
by stable disease for greater than or equal to 24 weeks, producing an overall clinical benefit
of 68%. The median time to progression was 42 weeks in this population [32]. Garcia-Saenz
et al., have addressed this question as well [33]. Patients who were refractory to
anthracycline and taxane therapy with metastatic breast cancer were given
cyclophosphamide 50 mg daily, methotrexate 1 mg/kg every 14 days and bevacizumab 10
mg/kg every 14 days. Trastuzumab was given for HER2-overexpressing tumors. A total of
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22 patients were evaluable. After a median follow-up of 7.7 months, no patients had a
complete response, 31.8% had a partial response and 31.8% had stable disease for a
prolonged duration of greater than or equal to 24 weeks. The clinical benefit rate was 63.6%
and median PFS was 7.5 months. The median overall survival was 13.6 months [33].
The North Central Cancer Treatment Group trial N0432 tested bevacizumab combined with
docetaxel and capecitabine as first-line chemotherapy for patients with metastatic breast
cancer. Patients received bevacizumab 15 mg/kg and docetaxel 75 mg/m2 on day 1 and
capecitabine 825 mg/m2 twice per day on days 1–14 every 21 days for a median of seven
cycles. A total of 45 patients were evaluated in all. Two patients had complete responses and
20 patients had partial responses, yielding an overall response rate of 49%. Nine patients had
stable disease for more than 6 months, giving a clinical benefit rate of 69%. The median
response duration was 11.8 months, and median overall survival was 28.4 months. The
median PFS was 11.1 months [34].
Randomized trials for metastatic breast cancer
A large randomized Phase III trial by Miller et al. randomly assigned patients with
metastatic breast cancer who previously had received treatment with an anthracycline and a
taxane to receive capecitabine 2500 mg/m2 twice daily on days 1–14 every 3 weeks, either
alone or with bevacizumab 15 mg/kg on day 1 [35]. In all, 462 patients were enrolled in the
study. The addition of bevacizumab significantly increased the response rate from 9.1 to
19.8%, but this did not translate to a longer PFS (4.86 vs 4.17 months). The overall survival
was 15.1 versus 14.5 months, which was not significantly different [35].
The Eastern Cooperative Oncology Group (ECOG) trial, E2100, was a large Phase III trial
testing the use of bevacizumab for the initial treatment of metastatic breast cancer. A total of
722 patients were enrolled who had metastatic breast cancer and had not received any prior
cytotoxic chemotherapy; however, prior hormonal therapy or adjuvant cytotoxic therapy was
allowed. HER2-positive patients were eligible only if they had received trastuzumab and
constituted a minority of patients in this study. Patients were randomized to receive
paclitaxel 90 mg/m2 on days 1, 8 and 15 every 4 weeks, either alone or with bevacizumab 10
mg/kg on days 1 and 15. The combination showed a significant prolongation of PFS
compared with paclitaxel alone, with a median of 11.8 versus 5.9 months. The objective
response rate increased from 21.2 to 36.9%, but the overall median survival was similar
between the two groups, 26.7 versus 25.2 months [36].
Another Phase III trial that employed bevacizumab was the AVADO trial [37]. This study
looked at bevacizumab (7.5 or 15 mg/kg) given every 3 weeks versus placebo with
docetaxel as first-line treatment of HER2-negative locally recurrent or metastatic breast
cancer. It was shown that only the higher dose of bevacizumab resulted in a superior median
PFS of 10.1 months, compared with 8.2 months for placebo in an unstratified analysis (p =
0.006). Also, patients who received the higher dose of bevacizumab had a significant
improvement in response rates compared with placebo (64 vs 46%; p = 0.001). Interestingly,
there was no significant increase in the toxicity of docetaxel with the addition of
bevacizumab. A subset analysis of patients ≥65 years of age showed there was a similar
increase in survival, although this was not statistically significant [38]. There was also no
significant increase in adverse events in this population.
The RIBBON-1 trial was a randomized Phase III trial utilizing bevacizumab as first-line
treatment of patients with HER2-negative, locally recurrent or metastatic breast cancer. Over
1200 patients were enrolled and median PFS was shown to increase in all treatment groups
receiving bevacizumab, although there was no increase in overall survival in any group [39].
RIBBON-2 was a Phase III study that compared bevacizumab with standard chemotherapy
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versus standard chemotherapy alone in HER2-negative metastatic breast cancer. In total, 684
patients were enrolled and a statistically significant benefit in PFS was seen, with an
increase from 5.1 to 7.2 months. Again, no statistically significant difference was shown in
overall survival. The safety profile and overall response rates were similar to those seen in
prior studies [40].
Recently, the early results of the AVEREL trial were presented. This was a randomized
Phase III trial that combined bevacizumab with trastuzumab and docetaxel as first-line
therapy for the treatment of HER2-positive locally recurrent or metastatic breast cancer. A
total of 421 patients were treated in this study, and the addition of bevacizumab increased
PFS from 13.9 to 16.8 months, which was found to be statistically significant when
evaluated by an Independent Review Committee [41]. In addition, when patients were
stratified as being high-VEGF producers versus low-VEGF producers, those who were high
producers were found to have a prolonged median PFS of 13.6 months when treated with
bevacizumab compared with only 8.5 months for those treated with trastuzumab and
docetaxel alone. This study shows potentially promising results, and further evaluation is
pending to determine biomarkers that may help identify which patients may benefit.
Trials in the neoadjuvant setting
A few trials have evaluated the use of bevacizumab as initial therapy for metastatic breast
cancer or as part of a neoadjuvant treatment regimen in patients with locally advanced breast
cancer. One study evaluated the effect of bevacizumab as neoadjuvant therapy for patients
with inflammatory breast cancer. Wedam et al. performed a pilot study and treated 21
patients with previously untreated stage III or IV inflammatory and locally advanced breast
cancer with bevacizumab 15 mg/kg on day 1 for one cycle followed by six cycles of
bevacizumab combined with doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 on day 1 every
3 weeks [42]. Patients underwent surgery at a minimum of 4 weeks after the seventh cycle.
Radiation therapy was started after complete recovery from surgery. Eight additional cycles
of bevacizumab were given postoperatively every 3 weeks. Hormonal therapy was given as
indicated. As assessed by imaging, 14 patients had a partial response and no patients had a
complete response, yielding an overall response rate of 67%. Five patients had stable disease
and two had progressive disease. The median PFS was 25.3 months and overall survival was
90.5% at 1 year and 80.0% at 2 years [42]. Tumor biopsies and dynamic contrast-enhanced
MRI were obtained at baseline and after cycles one, four and seven. After receiving
bevacizumab alone, dynamic contrast-enhanced MRI showed a significant decrease in blood
flow. This decrease was greater than that observed after the administration of chemotherapy,
although a decrease persisted. There was also a decrease in the presence of the
phosphorylated VEGF receptor in tumor cells and increased apoptosis, which persisted after
the administration of chemotherapy.
Greil et al. evaluated the use of bevacizumab combined with capecitabine and docetaxel as
neoadjuvant therapy for breast cancer [43]. Patients had received no prior systemic therapy
and had invasive HER2-negative breast cancer, that was T2–T4c with any nodal stage (N)
and showed no evidence of metastatic disease. Patients were treated with six 21-day cycles
of bevacizumab 15 mg/kg on day 1 of cycles one to five, docetaxel 75 mg/m2 on day 1 of
each cycle, and capecitabine 950 mg/m2 twice daily for 14 days of each cycle. Surgery was
performed 2–4 weeks after the completion of neoadjuvant therapy, and was followed by
radiation, chemotherapy and hormonal therapy as determined by institutional standards. A
total of 18 patients were included, 15 of which (83%) were able to undergo breast-
conserving surgery. An objective response, either complete or partial, or stable disease was
observed in 72% of patients, while only 22% had a pathologic complete response, which
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was comparable with that previously seen after treatment with capecitabine and docetaxel
alone [43].
One study looked specifically at patients with unfavorable prognostic features, such as
estrogen and progesterone receptor staining of less than 10% of cancer cells, and T2–4c. All
patients were treated with epirubicin 25 mg/m2 on days 1 and 2, cisplatin 60 mg/m2 on day
1, and fluorouracil 200 mg/m2 on day 1 to 21 for four courses. Paclitaxel 90 mg/m2 was
given on days 1, 8 and 15 every 28 days for three courses. Bevacizumab 10 mg/kg was
given every 14 days for six courses during paclitaxel treatment. Patients with inflammatory
endocrine-responsive breast cancer received chemotherapy plus endocrine therapy with
letrozole 2.5 mg daily ± GnRH analog with respect to menopausal status. A total of 30
patients were evaluated and 25 (83%) had a partial response. One patient (3%) had a
complete response, giving an overall response rate of 87%. Two patients (7%) had stable
disease and two patients (7%) had progressive disease. All patients underwent surgery, and a
pathologic complete response was seen in ten patients (33%), all of whom received
bevacizumab [44].
Baar et al. also examined bevacizumab in the neoadjuvant setting [45]. They randomized 49
patients with inoperable breast cancer to receive either two cycles of docetaxel alone 35 mg/
m2 weekly for 6 weeks, or the addition of bevacizumab 10 mg/kg every other week for a
total of 16 weeks, followed by docetaxel. The overall clinical response rate was 78%.
Nineteen patients in each arm became operable and three patients in each arm had a clinical
response but were inoperable. Three patients in the docetaxel arm and one patient in the
bevacizumab arm had progressive disease. One patient receiving bevacizumab also
experienced a treatment-related death during neoadjuvant therapy. There was no significant
difference between the groups in either 60-month PFS (47.3% in docetaxel arm vs 37.2% in
bevacizumab arm) or overall survival (57.1% in the docetaxel arm vs 57.6% in the
bevacizumab arm) [45].
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-40 trial has accrued
1206 patients to evaluate the use of bevacizumab in the neoadjuvant setting [46]. In this
trial, operable HER2-negative breast cancer patients were randomized to receive docetaxel
with or without the addition of capecitabine or gemcitabine, followed by doxorubicin plus
cyclophosphamide. In addition, half received bevacizumab with the first six doses of
chemotherapy preoperatively. Patients then underwent surgery, followed by an additional
ten doses of bevacizumab for those who received it preoperatively. Results from this trial
were recently published and demonstrated that the addition of bevacizumab to neoadjuvant
chemotherapy significantly increased the rate of pathological complete response in the
breast from 28.2 to 34.5% (p = 0.02) [46]. The effect of bevacizumab was greater in patients
with hormone receptor-positive cancers than in the triple-negative subset. Results from a
similar trial (GeparQuinto) from the German Breast Group, also recently published, were
curiously different from the B-40 results [47]. This trial utilized an anthracycline and
docetaxel-based chemotherapy regimen in 1948 patients with HER2-negative early-stage or
locally advanced breast cancer. They also observed a significant increase in pathological
complete response (in breast and nodes) with the addition of bevacizumab in the overall
study population (14.9 vs 18.4%; p = 0.04), but in the German trial the difference was
greater in the 663 patients with the triple negative cancers (27.9 vs 39.3%; p = 0.003) [47].
Future issues
Patients with metastatic breast cancer are faced with a poor prognosis and the search for
therapies to improve this is ongoing. The results of the E2100 trial led to accelerated
temporary approval by the US FDA of bevacizumab plus paclitaxel as first-line therapy in
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patients with metastatic breast cancer in 2008 [101]. Recently, this approval was withdrawn
because it was felt that, after evaluating further trials, bevacizumab does not prolong overall
survival or provide a benefit in slowing disease progression. The available data indicate that
bevacizumab for the treatment of HER2-negative metastatic breast cancer does not clearly
provide a survival benefit, since there is an increase in PFS, but not overall survival (Table
1) [48–50]. Early results from a few studies have shown improvement in pathologic
response rates, but this has not yet been shown to translate into an improvement in overall
survival. Additional data are needed from these early trials.
The ATHENA trial, which is a registry trial, treated patients with locally recurrent or
metastatic breast cancer, and has shown with long-term follow-up that continuation of
single-agent bevacizumab in patients without progression can be done with minimal toxicity
and possibly long-term disease control [51]. Median overall survival was 30.0 months in
these patients versus 18.4 months for those who discontinued bevacizumab during or before
their chemotherapy regimen. Recently, they have shown that the risk profile in patients older
than 70 years of age is no different to that of younger patients except for additional
hypertension, although this risk was manageable [52]. Given the long-term safety data,
extended administration of bevacizumab could potentially be a feasible method for treatment
that may provide a benefit in overall survival, and needs to be investigated further. Certain
populations of patients have not been completely addressed with the current trials. The
Cancer and Leukemia Group B (CALGB) has sponsored three trials, CALGB 40502, 40503
and 40603, which are continuing, despite the FDA’s determination to examine the utility of
bevacizumab in patients with hormone receptor-positive breast cancer receiving endocrine
therapy and those with triple-negative breast cancer. Results from these trials may help to
determine whether there is still a role for bevacizumab in the treatment of breast cancer.
There are several factors that may have contributed to the failure to show an overall survival
benefit of bevacizumab. First, most of the patient populations being studied are ones that
have proven to be resistant to conventional therapies and thus may represent a more
aggressive biology. Second, it is difficult to compare the results of these trials given the
variety of treatment regimens utilized. Since there is no standardized method of
administration of bevacizumab, many patients had limited administration due to toxicity,
and the major end point for most is not overall survival. Finally, selection of patients for
bevacizumab is challenging, because we lack reliable biomarkers to evaluate the activity for
the agents. Studies have shown a relationship with HER2 overexpression and VEGF
expression in human cancer cells in vitro [53]. A Phase I study looked at utilizing the
combination of bevacizumab and trastuzumab to treat patients who are HER2-positive and
showed no prohibitive toxicities with utilizing two humanized monoclonal antibodies, and
there was a 55% overall response rate identified in these patients, which is promising [54].
The identification of biomarkers such as HER2 that may identify patients who might benefit
from bevacizumab may be the key to determining which patients should receive this therapy
[48,49]. This might be accomplished with the use of tissues collected in neoadjuvant trials
such as B-40 and GeparQuinto, although both of these studies excluded HER2-positive
breast cancers.
In addition, the question must be addressed regarding whether PFS is a reliable end point to
study. The majority of studies utilizing bevacizumab have only been able to show a
prolongation in PFS, but this has not translated to overall survival. Other factors may be
contributing to the lack of overall survival, such as the biology of the individual tumors
being studied and the other therapies utilized in a treatment regimen aside from
bevacizumab. Further study is needed to see if these differences are sustainable in certain
populations.
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Finally, as is the case for any potent drug, bevacizumab is also not free from adverse effects.
The most common side effects reported with bevacizumab include headache, nausea,
hypertension and wound infection. Other more serious and sometimes fatal side effects can
include left ventricular systolic dysfunction, gastrointestinal perforation, thromboembolism,
hemorrhage or sepsis. The initial decision for approval of bevacizumab was mainly based on
results from the E2100 trial, which reported similar adverse hematologic, gastrointestinal
and musculoskeletal effects for both groups [36]. Side effects that were more common in the
group that received bevacizumab were wound infection, fatigue, headaches and
hypertension. There were no serious adverse events reported except for cerebrovascular
ischemia in 1.9% of patients receiving bevacizumab, and so it was felt that the toxicities of
bevacizumab was minimal and similar to other prior reports. Since the approval of
bevacizumab, other trials have reported more significant side effects; based on the additional
data, the FDA decided that its severe side effects outweighed the benefits of this drug. That,
along with the lack of improvement in overall survival, led to the approval being withdrawn
[102]. Of particular concern has been an increase in left ventricular dysfunction, as shown
by a recently published meta-analysis [55].
Emerging new target: lymphangiogenesis
Although the critical impact of lymph node metastasis on prognosis and the progression of
breast cancer through lymph node metastasis has been well established in patients [56], the
active involvement of the lymphatic system in cancer metastasis has been revealed only
recently, following the identification of molecular markers of lymphatic vessel development
[57,58]. Together with the fact that lymphatic vessels are the main route of drainage of
extracellular fluid, lymphangiogenesis, the generation of new lymphatic vessels from
preexisting ones, has recently emerged as a new target for cancer therapy [57].
Lymphangiogenesis has been found to be controlled by VEGF-C and -D, which are
associated with a number of human tumor types [58]. For metastasis to the draining lymph
nodes to occur, the cancer cells need to access the draining lymphatic vessels to reach the
regional lymph nodes, and tumor-induced lymphangiogenesis appears to promote this
process by increasing the number of entry sites into the lymphatic system [59]. In fact,
recent evidence suggests that lymphangiogenesis plays a key role in the development of
nodal metastases from various human malignancies [60]. Tumor-induced lymphatic vessel
density has correlated with metastasis to the draining lymph nodes, distant metastases and
poor prognosis [58,61–63]. These studies suggest that expression of lymphangiogenic
growth factors by tumor cells induces lymphangiogenesis, which promotes metastasis via
lymphatic vessels to draining lymph nodes and beyond.
VEGF-C also promotes circumferential enlargement of the collecting vessels, leading to
increased lymph flow and transport of tumor cells, as well as accommodation of larger
tumor cell clusters [64–66]. Experimental inhibition of this process in animal models has
suggested that lymphangiogenic growth factors facilitate the metastatic spread of tumor cells
via lymphatic vessels [65]. Furthermore, lymphangiogenic growth factors produced by the
primary tumor appear to act at a distance by inducing lymphangiogenesis, or sinusoidal
hyperplasia, in the sentinel lymph node before the arrival of the first metastatic cells [67,68].
Expansion of the lymphatic vasculature in premetastatic lymph nodes has been confirmed in
mouse models of breast carcinomas [69], indicating that lymphangiogenesis in the
premetastatic lymph node fosters tumor dissemination by creating a favorable environment
for cancer cells.
As described in previous sections, several clinical trials have demonstrated that not all
patients respond to bevacizumab, and those that do can acquire resistance [70]. Furthermore,
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patients with high levels of VEGF-C expression were shown to have worse outcomes [71].
Based upon the fact that VEGF-C plays a key role in lymphangiogenesis, it is possible that a
contributing factor in the poor outcomes of some patients may be due to a failure to inhibit
the effects of VEGF on lymphangiogenesis [72].
Given the fact that draining lymph nodes are usually the first site of metastasis, targeting
lymphangiogenesis and nodal metastasis is expected to be a key new target for the
development of new therapies for cancer. Considering the strong associations among tumor-
induced lymphangiogenesis, regional lymphatic spread, distant metastasis and survival, the
inhibition of tumor lymphatic vessels seems to be an attractive target. Inhibition of
lymphangiogenic factors or receptors has had a significant antimetastatic efficacy in several
experimental models (Figure 1) [66,73]. Moreover, a combination of chemotherapy and
antilymphangiogenic therapy might be more effective in eliminating metastatic cells while
preventing the rebuilding of the damaged lymphatic vasculature [74]. Ramucirumab, a novel
compound that targets both angiogenesis and lymphangiogenesis, is currently being
evaluated in a Phase I clinical trial and is reported to have an impressive, albeit early, effect
on both stable disease and partial responses in a variety of tumor types [75]. Moreover, the
first inhibitor of lymphangiogenesis, the VEGF receptor-3-targeting monoclonal antibody
IMC-3C5, has recently entered a Phase I clinical trial for patients with advanced solid
tumors [76,103]. In the future, tailored treatments consisting of combinations of
chemotherapy and targeted therapy against both angiogenesis and lymphangiogenesis are
expected to improve patient outcomes. This progression to the clinic may be guided by new
avenues of research such as the identification of biomarkers that predict response to
treatment.
Conclusion
Bevacizumab is an angiogenesis inhibitor that has shown promising results in the treatment
of various cancers. Its role in the treatment of breast cancer is not clearly defined by the
current trials; despite improvement in PFS, this has not translated into improvement in
overall survival. Further studies are needed to address whether longer-term administration of
bevacizumab will show significant improvement in overall survival for patients with
metastatic breast cancer. The development of methods of evaluation of angiogenesis will
allow us to monitor the effectiveness of such therapies. Also, the identification of
biomarkers may delineate which patients will benefit from antiangiogenic therapy. These
therapies, and new ones in development, may also function to inhibit lymphangiogenesis
and, thereby, inhibit the progression and development of metastatic disease.
Future perspective
Agents for the treatment of breast cancer are continuing to evolve. Currently, the role for
antiangiogenic agents in the treatment of breast cancer is not well defined. In the future we
may be able to develop biomarkers that may help us better identify which patients will
benefit from certain treatments and we will therefore be able to provide individualized
therapy for patients. Targeting a combination of the mechanisms of cancer growth and
metastasis, including lymphangiogenesis, will be an exciting frontier for the development of
new agents in the treatment of breast cancer.
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Executive summary
Role of angiogenesis in cancer progression
▪ VEGF-A is a major proangiogenic protein expressed in a majority of breast
cancers.
▪ An antibody to VEGF-A has been shown to decrease microvessel density
convincingly in preclinical models.
Experimental assays to measure angiogenesis
▪ Several methods of measuring cell proliferation, migration and invasion have
been developed for use in vivo and in vitro, but can be very labor intensive
and inconsistent.
Clinical trials with bevacizumab
▪ Multiple randomized Phase III trials have shown that the addition of
bevacizumab to various chemotherapy regimens improves overall response
and progression-free survival in most of the trials for the treatment of breast
cancer, but no study has shown a significant improvement in overall survival.
▪ Reports of toxicity have ranged from mild side effects of headache,
hypertension or nausea, to fatal side effects of gastrointestinal perforation or
hemorrhage.
▪ The National Surgical Adjuvant Breast and Bowel Project B-40 and
GeparQuinto trials have shown that bevacizumab added to chemotherapy
may increase pathologic complete response rates in certain patient
populations.
▪ Current ongoing trials are being performed to study certain patient
populations (e.g., hormone receptor-positive, HER2-negative or HER2-
positive) to define a potential role for bevacizumab.
Emerging new target: lymphangiogenesis
▪ Lymphangiogenesis plays a key role in the development of lymph node
metastases and is regulated in part by VEGF-C.
▪ Antilymphangiogenic agents may be required to prevent progression of
disease more effectively in patients with breast cancer.
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Figure 1. Inhibitors of VEGF-A, -B, -C/D, and their receptors
Bevacizumab is a monoclonal antibody against VEGF-A. VEGF and VEGF-C/D traps are
fusion proteins that bind to VEGF-A, or VEGF-C/D, respectively. Ramucirumab
(IMC-1121B) and IMFC-3C5 are monoclonal antibodies against VEGF receptor-2 and
VEGF receptor-3, respectively. Thick arrows express major pathways and thin arrows
express reported, but minor, pathways.
Ab: Antibody; VEGFR: VEGF receptor.
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